Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder

World Journal of Urology

Volumn 15, Issue 2, 1997, Pages 89-95

  Alfthan, Olof ^a   Jauhiainen, Kari ^a   Kaasinen, Eero ^a   Liukkonen, Tapani ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER TUMOR; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; ONCOLOGY; PREVENTIVE MEDICINE; REVIEW; TRANSITIONAL CELL CARCINOMA; UROLOGY;

ADMINISTRATION, INTRAVESICAL; CARCINOMA, TRANSITIONAL CELL; HUMANS; MEDICAL ONCOLOGY; PREVENTIVE MEDICINE; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 0030634845     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02201978     Document Type: Article

References (64)

1. Alfthan O, Jauhiainen K. Kangas L, Kapylii H (1986) Superficial urinary bladder caneinoma: Chemotherapy, rclinoids and prevention of relapses. Int .1 Immunother II: 5 15
2. Bohle A. N owe CH. Ulmer A.I. Musehold J. Gerdes J, Hofsstetter AG, Flad HD (1990) Elevations of the cytokines interleukin-1, interleukin-2 and tumor neerosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol 144: 59-64
3. Bohle A, Thanhöuser A, Ulmer A.I. Ernst M. Elad HD. Jocham D (1993) Dissecting the immunological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCGactivated killer (BAR) cell phenomen. J Urol 150: 1932-1939
4. Carbin B-E (1990) Prognostic factors in urinary bladder cancer. Thesis Kongelige Carolinska Medico Chirurgiska Institute!. Stockholm
5. DeBruyne FMJ, Meijden ADPM van der. Geboers ADH. Franssen MPH, Leeuwen MJW van, Steeremberg PA. de.Iong WM, Ruitenberg JJ (1988) BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. Urology 31: 20-25.
6. deVere White R, Cockburn AC (1985) Predicting the invasive potential of bladder cancer. World J Urol 3: 73-75
7. Droller MJ (1980) Transitional cell carcinoma: an overview. Urol Clin North Am 7: 519-521
8. Droller MJ (1987) Biologic response modifiers in genitourinary neoplasia. Cancer 60: 635-644
9. Eksborg S, Nilsson SO. Edsmyr F (1980) Intravesical instillation of adriamycin. A model for standardization. Eur Urol 6: 218-220
10. Fradet Y (1995) Treatment of superficial bladder cancer. Curr Opin Urol 5: 267-271
11. Engeland A, Haldorsen T. Tretli S, Hakulinen T. Hörte LG. Luostarinen T, Magnus K. Schon G, Sigvaldason H. Storm HH, Tulinius H, Vaittinen P (1993) Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. APMIS [Suppl] 38: 101
12. Heikkinen A (1984) Epithelial tumours of the urinary bladder; a clinical study. Thesis, Helsinki University, Helsinki
13. Jauhiainen K (1985) Detecting mitomycin C in human plasma during intravesical therapy. Int Urol Nephrol 17: 155-158
14. Jauhiainen K. Alfthan O (1984) Die Behandlung von Carcinoma in situ der Harnblase mit lokaler Adriamycin instillation. Aktuel Urol 15: 129-133
15. Jauhiainen K, Alfthan O (1984) Adriamycin instillations as recurrence prophylaxis in superficial urinary bladder cancer. Ann Chir Gynaecol 73: 206-210
16. Jauhiainen K, Nieminen AL, Käpylä H, Alfthan O (1983) Optimising mitomycin C activity during intravesical instillation. Urol Res 11: 59-62
17. Jauhiainen K. Alfthan O (1987) Mitomycin C and doxorubicin instillation as recurrence prophylaxis in superficial (Ta-1) urinary bladder cancer. Br J Urol 60: 54-59
18. Jauhiainen K, Eksborg S, Kangas L. Perilä M. Alfthan O (1985) The absorption of doxorubicin and mitomycin C in perioperative instillation. Eur Urol 11: 269-272
19. Jauhiainen K, Kangas L, Käpylä H. Alfthan O (1985) Intravesical cytostatics: pH-dependence of antitumour activity. Urol Res 13: 19-21
20. Jauhiainen K, Sotarauta M, Permi J, Alfthan O (1986) Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. Eur Urol 12: 32-37
21. Jauhiainen K, Rintala E, Kaasinen E. Ruutu M. Alfthan O (1991) Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer. Arch Esp Urol 43. [Suppl II]: 159-164
22. Jauhiainen KE, Alfthan OS, the Finnbladder Group (1991) Instillation therapy in superficial urinary bladder cancer. Scand J Nephrol Urol 138: 179-185.
23. Kaasinen ES. Kalliomäki PH W, Alt'tlian OS. Timonen TT (199?) Bacillus Calmette-Guérin sensitise.-» fresh transitional cancer cells and T 24 cell line to non-MHC-restricted cytoloxicity in vitro. Br J Urol 72: 897 906
24. Kangas L. Grönroos M. Nieminen ML (1984) Bioluminescence of cellular ATP: a new method for evaluating cytotoxic anents in vitro. Med Biol 62: 338 -343
25. Kurth KM. Schröder FH. Turin LJ. Ay R, Pavone-.Vlacaluso M. Debryune F. dePauw M. Dalesio O. tenKate F. members of EORTC (1984) Adjuvant chemotherapy of superficial transitional cell bladder carcinoma preliminary results of a European Organization for Research on Treatment of Cancer Randomized trial comparing doxorubicin hydrochloride. ethoglucid and transurethral resection alone. J Urol 132: 258 262
26. Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573-580
27. Lamm DL. Reichert DF. Harris SC. Lucio RM (1982) Immunotherapy of m urine transitional cell carcinoma. J Urol 128: 1104-1108
28. Lamm DL, Thor DE, Stogdill VD. Rawdin HM (1982) Bladder cancer immunotherapy. J Urol 128: 931 935
29. Lamm DL. Stogdill VD, Stogdill BJ, Crispen RG (1986) Complications of bacillus Calmette-Guérin immunotherapy in 1.278 patients with bladder cancer. J Urol 135: 272-274
30. Lamm DL. Blumenstein BA, Crawford ED. Montie JE. Scardino P, Grossman HB, Stanisic TH, Smith JA Jr. Sullivan J, Sarosdy MF. Crissman JD. Coltman ÇA (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell earcinoma of the bladder. N Engl J Med 325: 1205-1209
31. Lipponen P (1990) Histoquantitative techniques as prosnosticators in transitional cell carcinoma of the urinary bladder. Thesis. Kuopio University, Kuopio
32. Lipponen PK. Liukkonen TJO (1994) Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J Cancer Res Clin Oncol 121:44-50
33. Lipponen PK, Eskelinen MJ, Jauhiainen K. Harju E, Terho R, Haapasalo H (1992) Independent clinical, histological and quantitative prognostic factors in transitional-cell bladder tumours, with special reference to mitotic frequency. Int J Cancer 51: 396-403
34. Liukkonen TJO. Lipponen PK. Helle M, Haapasalo HK, Nordling S, Rajala P, the Finnbladder Group (1996) Expression of M IB-1, mitotic index and S-phase fraction as indicators of cell proliferation in superficial bladder cancer. Urol Res 24: 61-66
35. Liukkonen TJO. Lipponen PK. Helle M, Jauhiainen KE. the Finnbladder III Group (1996) The immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. J Urol (in press)
36. Malmström PU, Busch C, Norlén BJ (1987) Recurrence, progression and survival in bladder cancer. A retrospective analysys of 232 patients with > = 5 year follow-up. Scand J Urol Nephrol21: 185-195
37. Melicow MM, Hollowell JW (1952) Intraurothelial cancer/ carcinoma in situ. Bowen's disease of the urinary system: discussion of thirty cases. J Urol 68: 763-772
38. Messing E. deKernion JB (1985) Chemotherapy of bladder cancer."In: Zingg EJ, Wallace DMA (eds) Bladder Cancer. Springer. New York Berlin Heidelberg, pp 235-262
39. Mizutani Y, Nio Y, Fukumoto M, Yoshida O (1992) Effects of bacillus Calmette-Guérin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 69: 537-545
40. Morales A, Eidinger O. Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial tumors. J Urol 116: 180-183
41. Mostofi FK. Sobin LH, Torloni H (1973) Histological typing of urinary bladder tumours number 10. WHO. Geneva
42. Murphy WM (1989) Diseases of the urinary bladder, urethra, ureters, and renal pelvis. In: Murphy WM (ed) Urological pathology. Saunders, Philadephia, pp 134 146
43. Raitanen MP. Nieminen P. Tammela TLJ (1995) Impact of tumour grade, stage, number and size, and smoking and sex on survival in patients with transitional cell carcinoma of the bladder. Br J Urol 76: 470-474
44. Raitanen MP. Tammela TLJ, Kallioinen M. Isola J (1996) p53 accumulation and DNA ploidy and tumor progression of bladder cancer. J Urol (in press)
45. Rajala E. Kaasinen E. Rintala E, Jauhiainen K. Nurmi M. Alflhan O, Lähde M (1992) Cytostatic effect of different strains of bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol Res 20: 215217
46. Rajala E. Nurmi M, Alanen K. Lähde M (1993) Cytostatic effect of interferon-alpha on human bladder cancer cells in vitro. Ann Chir Gynaecol 82: 50 53
47. Ratliff TL. Gillen D. Catalona WJ (1987) Requirement of thymus dependent immunoresponse for BCG-mediated antitumour activity. J Urol 137: 155 158
48. Ratliff TL, Kavoussi LR, Catalona WJ (1988) Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 139: 41014
49. Rintala E. Jauhiainen K, Alfthan O, Hansson E, Juusela H. Kanerva K. Korhonen H. Permi J, Sotarauta M, Vaalasti T. Viitanen J. Usenius R (1991) Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol 20: 19-25
50. Rintala E, Jauhiainen K. Rajala E, Ruutu M. Kaasinen E, Alfthan O. the Finnbladder Group (1995) Alternating mitomycin C and bacillus Calmette-Guérin instillation therapy for carcinoma in situ of the bladder. J Urol 154: 2050-2053
51. Rintala E. Jauhiainen K, Kaasinen E. Nurmi M, Alfthan O. the Finnbladder Group (1996) Alternating mitomycin C and bacillus Calmette-Guérin instillation prophylaxis for recurrent papillary stages (Ta to Tl) superficial bladder cancer. J Urol 156 (in press)
52. Schalken JA, Debruyne FMJ (1995) Prognostic indicators of bladder cancer. Curr Opin Urol 5: 272-274
53. Silverberg E (1987) Statistical and epidemiologic data on urologie cancer. Cancer 60: 692-718
54. Soloway MS (1983) Surgery and intravesical chemotherapy in the management of superficial bladder cancer. Semin Urol I: 23-33
55. Soloway MS (1982) Intravesical chemotherapy for superficial bladder cancer. In: Spiers A (ed) Chemotherapy and urological malignancy. Springer, New York Berlin Heidelberg, pp 50-71
56. Soloway MS (1984) Rationale for intensive intravesical chemotherapy. In: Kurth KH. Debruyne FMJ. Schoeder FH. Splinter TAW. Wagener TDJ (eds) Progress and controversies in oncological urology. Liss, New York, pp 287 -295
57. Soloway MS. Masters S (1980) Urothelial susceptibility to tumor cell implantation. Cancer 47: 1158-1163
58. Steg A. Boiteux JP (1984) Bladder carcinoma in situ: conservative versus aggressive approach. In: Kurth KH. Debruyne FMJ. Schoeder FH, Splinter TAW. Wagener TDJ (eds) Progress and controversies in oncological urolosiy. Liss. New York, pp 263 274
59. Timberg G. Rahu M. Gornoi K, Tiiu A. Baburin A (1996) Bladder cancer in Estonia. 1968-92: incidence, mortality, prevalence and survival. Scand J Urol Nephrol (in press)
60. UICC (1989) TNM classification of malignant tumours, 4th fully revised edn. Springer, Berlin Heidelberg New York
61. Vaara J. Tukiainen H (1989) BCG-rokotus. Suom Lääkärilehti 44: 388-393
62. Wolf H, Höjgaard K (1983) Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future occurences. Lancet, II: 134-136
63. Zbar B, Bernstein ID. Bartlett GL, Hanna MG Jr, Rapp HJ (1972) Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastasis after intralesional injection of living Mvcohactcriiim bovi.s. Int J Cancer 49: 119-130
64. Zincke H. Utz DC, Farrow GM (1985) Review of Mayo Clinic experience with carcinoma in situ. Urology 26: 39-46